Thumbnail screenshot of methadone results-at-a-glance summary

Methadone Results-at-a-Glance

Read the methadone Results-at-a-Glance summary.

Nearly 20% of children in the United States are classified as obese. These children receive medicines more often than children without obesity, and the doses of medicines they receive are often based on body weight. How obesity impacts the way children process medications was not well understood. The “Use of Physiologically-based Pharmacokinetic Modeling to Inform Dosing of the Opioid Analgesics Fentanyl and Methadone in Children with Obesity” study was conducted to learn how children’s age, obesity status, and genes impact the way their bodies process methadone and fentanyl.

PTN Publications Policy Version 5.0

View the Publications Policy Version 5.0.

This PTN Publications Policy applies to information that represents PTN, is supported by PTN, or uses data provided by PTN. Examples of such information includes PTN Publications such as abstracts, manuscripts, slide decks, and texts of oral or other presentations. Additionally, this information can be PTN Public Presentations, such as text for social media or public-facing websites.

Thumbnail screenshot of lorazepam results-at-a-glance summary

Lorazepam Results-at-a-Glance

Read the lorazepam Results-at-a-Glance summary.

Status epilepticus (SE) is a serious condition that affects the brain. SE can be caused by medical conditions, illnesses, or injuries. A preferred treatment for SE is lorazepam. However, lorazepam is not approved by the FDA for children under 18 years old. This summary is for a study performed by the Pediatric Trials Network (PTN). The study was needed to find out how children with SE process lorazepam.